A Sampling of Highlights from the Literature.

Abstract

What We're Reading| December 02 2022 A Sampling of Highlights from the Literature: Article Recommendations from Our Deputy and Senior Editors Author & Article Information Online Issn: 2326-6074 Print Issn: 2326-6066 ©2022 American Association for Cancer Research2022American Association for Cancer Research Cancer Immunol Res (2022) 10 (12): 1421. https://doi.org/10.1158/2326-6066.CIR-10-12-WWR Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn MailTo Tools Icon Tools Get Permissions Cite Icon Cite Search Site Article Versions Icon Versions Version of Record December 2 2022 Citation A Sampling of Highlights from the Literature: Article Recommendations from Our Deputy and Senior Editors. Cancer Immunol Res 1 December 2022; 10 (12): 1421. https://doi.org/10.1158/2326-6066.CIR-10-12-WWR Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest Search Advanced Search D-2HG inhibits CD8+ T-cell function (from Alex Ritter, Jennifer Lippincott Schwartz and Gillian Griffiths via NIH Flickr) D-2-hydroxyglutarate (D-2HG), which accumulates in cancers with mutations in isocitrate dehydrogenase 1 (IDH1) and IDH2, can act as an oncometabolite by promoting cancer-cell intrinsic epigenetic alterations. Notarangelo et al. show in preclinical models that D-2HG also inhibits CD8+ T-cell proliferation, cytotoxicity, and IFNγ production, which are all critical for antitumor immunity. These effects, which are acute and reversible, occur because D-2HG alters CD8+ T-cell metabolism by inhibiting lactate dehydrogenase activity, thereby altering glycolytic flux and NAD(H) balance. Samples from patients with IDH-mutant glioma similarly show reduced lactate levels and IFNγ signatures, highlighting the clinical relevance of the data. Notarangelo G, …, Haigis MC. Science 2022 October 5;377:1519–29. NK cells with two CARs show enhanced antitumor activity (from NIAID via Wikimedia Commons) Natural killer (NK) cells engineered to... You do not currently have access to this content.